[Cost-Consequence Analysis of Vedolizumab Initiation Timing Strategies in Crohn’s Disease in Italy]
DOI:
https://doi.org/10.7175/fe.v27i1.1605Keywords:
Crohn’s Disease, Italy, Economic analysis, Biologics, Early, LateAbstract
BACKGROUND: Moderate-to-severe Crohn’s disease (CD) significantly impacts patients and the healthcare system. Timely initiation of biologic therapy is crucial for clinical outcomes and economic efficiency. In Italy, however, many patients eligible for treatment remain on “conventional” drugs, highlighting an undertreatment phenomenon. In this context, this study assessed the clinical and economic impact of early use of vedolizumab compared to delayed management, based on the multicenter LOVE-CD study.
MATERIALS AND METHODS: A cost-consequence model was developed from the perspective of the Italian National Health Service and Italian society. The objective was to compare two therapeutic strategies for CD management: early and late approaches, differing in disease duration and prior anti-TNF exposure. Efficacy data were drawn from the LOVE-CD study, while estimates of direct and indirect costs were derived from the National Tariff and literature. Two scenarios were analyzed: the base case evaluated treatment costs with vedolizumab, including the subsequent phase over 52 weeks; the second scenario, developed with a multidisciplinary panel of Italian experts, included direct costs of the pre-treatment phase, estimating the duration and costs of treatments administered before starting vedolizumab.
RESULTS: The base case analysis showed that the early approach reduces overall costs compared to the late approach in CD management, with a per-patient saving of €6,086 (–10%). The early approach also proved more efficient in terms of cost per responder, both for endoscopic response (–38%) and endoscopic remission (–47%). The scenario analysis extended the evaluation to include the pre-treatment phase: considering these additional costs, the per-patient saving rose to €44,893 (–43%), highlighting even greater economic efficiency for early treatment.
CONCLUSIONS: The results suggested that early initiation of vedolizumab therapy in moderate-to-severe CD can generate significant clinical and economic benefits. These findings support the adoption of more timely and personalized treatment strategies.
Additional Files
Published
Issue
Section
License
Copyright (c) 2026 Rossella Bitonti, Ilaria Bozzari, Eleonora Cerutti, Andrea Marcellusi, Agnese Miranda, Rita Monterubbianesi, Marco Vincenzo Lenti, Mariabeatrice Principi, Laura Vincenzi, Raffaella Viti
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
